Loading...

KURA KURA ONCOLOGY INC Expansion Plans 8-K Filing

KR N

KR

KURA ONCOLOGY INC

(KURA)

2025 8-K

Financial Results Update

Financial Update

Commercial Sale Announced

FDA Approval Granted

Quarterly Results

Milestone Payment Received

Stock Option Plan

Financial Statements

Clinical Trials

Product Expansion

Financial Statements

Financial Results

Positive Trial Results

New Lease Agreement

Management Changes

Stock Option Plan

Collaboration Agreement

Q3 Financial Results

Director Appointment

Financial Results Announcement

Amendment of 2014 Equity In...

Clinical Trial Enrollment

Earnings Reports

Financial Results Announcement

Financial Results and Clini...

Private Placement

Earnings Report

Lease Extension

Earnings Reports

Clinical Trial Results

Equity Incentive Plan Amend...

Earnings Reports

Publication of Clinical Tri...

Liquidity Concern at Silico...

Earnings Report

Resignation of Officer

Financial Update

External Links:

On December 2, 2025, Kura Oncology, Inc. reported its first commercial sale of KOMZIFTI (ziftomenib), which is expected to trigger a $135 million payment from Kyowa Kirin before year-end. KOMZIFTI was approved by the FDA on November 13, 2025.

AI Assistant

KURA ONCOLOGY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.